Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ABG | Ann: Final Director's Interest Notice - S Herman | 30/09/24 | 0 | 108 | |||
|
|||||||
ABG | Ann: Resignation of Non-Executive Director | 27/09/24 | 0 | 134 | |||
|
|||||||
ABG | Ann: Becoming a substantial holder | 26/09/24 | 0 | 121 | |||
|
|||||||
ABG | Ann: FY23 Results Presentation | 22/09/24 | 34 | 21K | |||
|
|||||||
ABG | Ann: Change of Director's Interest Notice - S Sewell | 20/09/24 | 0 | 136 | |||
|
|||||||
ABG | Ann: Notification regarding unquoted securities - ABG | 20/09/24 | 0 | 102 | |||
|
|||||||
ABG | Ann: Notification regarding unquoted securities - ABG | 20/09/24 | 0 | 103 | |||
|
|||||||
ABG | Ann: Executive Leadership Changes | 12:40 | 0 | 217 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |